DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Hannouf MB. et al.
Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen-or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
BMC cancer 2012;
12: 447
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.